Healwell AI Leadership to Pitch Growth Story Amid Market Jitters

Healwell AI executives to pitch growth story at Toronto conference. Firm targets 50% AI revenue growth in 2026 after record 2025 sales and first positive EBITDA.

Healwell AI's executive team is heading to a major Toronto investor conference with a compelling narrative of transformation, but faces the immediate challenge of calming market nerves. The company's stock has declined approximately 12.5% over the past 30 days, currently trading at 0.52 EUR, as investors await what management has signaled will be a soft first quarter for 2026.

CEO James Lee and President Dr. Alexander Dobranowski are scheduled to present at the Bloom Burton & Co. Healthcare Investor Conference on April 22, with one-on-one meetings planned for institutional investors. Their task is to convince the market that the company's long-term growth trajectory remains intact despite near-term headwinds. The presentation, set for between 2:00 and 2:30 PM ET, comes just weeks before the release of Q1 2026 results in May, which are seen as a critical test for the sustainability of the firm's recent turnaround.

That turnaround is significant. For the full 2025 fiscal year, Healwell AI reported record revenue from continuing operations of approximately 103.8 million Canadian dollars. More importantly, it achieved its first-ever positive adjusted EBITDA, a milestone many growth-stage companies in the health AI sector have yet to reach. The full-year adjusted EBITDA stood at 2.3 million CAD.

The company is aggressively refining its focus to become a pure-play AI and software firm. In a strategic move at the end of March, Healwell signed a letter of intent to sell its subsidiary, HEAL Access Canada, to AI Maverick Intel. The transaction, expected to close by the end of May, will net Healwell equity and a secured loan of five million US dollars, effectively completing its strategic pivot.

Central to its future is the launch of its unified AI platform, "Amadeus." A North American rollout is planned for the first half of 2026, with international expansion to follow by year-end. The platform already boasts a client base of more than 70 corporate customers. Management remains optimistic for the full year, targeting 50% growth in AI-related revenue and an adjusted EBITDA margin of around 10% by year-end. The plan is to build momentum progressively after the anticipated Q1 slowdown.

The company is operating in a favorable sector. In Q1 2026 alone, approximately $5.34 billion flowed into 105 digital health deals in the United States. Cross-condition AI solutions—Healwell's core segment—attracted $2.88 billion of that total. At the Toronto conference, Healwell will share the stage with competitors like WELL Health Technologies and its subsidiary WELLSTAR, who also present on April 22, offering a direct comparison with other major players in the Canadian health tech space.

The coming weeks, framed by the investor conference and the subsequent quarterly earnings, will provide a concrete roadmap against which the market will measure Healwell's ambitious growth targets.